Coming Down the Pike: Treating Epilepsy - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Coming Down the Pike: Treating Epilepsy


Pharmaceutical Technology
Volume 33, Issue 3, pp. 20
Scientists studying epilepsy have traditionally focused on the comings and goings of ions through molecular channels in nerve cells, and many current antiseizure therapies seek to modulate that dynamic. However, some people don't respond to channel-based therapies, causing scientists to look further for other molecular activities to target therapeutically in epilepsy management. A recent report suggests they may have found one. A paper published in Nature Medicine points to a possible inflammatory interaction between white blood cells and blood-vessel walls that appears to damage the barrier that prevents unwanted substances from flowing into or out of the brain, the so-called blood–brain barrier. The researchers found an increase in "sticky" adhesion molecules on both white blood cells and on the cells lining the blood vessels in the brain of mice in whom epileptic-like seizures had been induced. This interaction, they proposed, might be therapeutically blocked by monoclonal antibodies, thus reducing the severity and incidence of seizures. Source: P.F. Pabene et al., "A Role for Leukocyte–Endothelial Adhesion Mechanisms in Epilepsy," Nature Medicine 14, 1377–1383 (2008).

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here